NSRX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$19.67median target· current $3.44 (+471.8%)2 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.090.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$40.5MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 3.82
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- -316.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- —
Last earnings
Jun 30, 2026 · Estimate $-0.23 · Reported $-0.54
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Nasus Pharma Ltd.
Company profileNasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company is headquartered in Tel Aviv-Yafo, Israel.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- AMEX
- Country
- USA
- Currency
- USD
Company profile
- HQ
- YIGAL ALON 65, TEL AVIV-YAFO, ISRAEL
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$40.5M
Shares outstanding$11.7M
52W high$9.50
52W low$1.98
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent